Mammography Stocks List

Mammography Stocks Recent News

Date Stock Title
May 6 PHG Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report
May 5 HOLX Hologic Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
May 3 HOLX Hologic, Inc. (NASDAQ:HOLX) Q2 2024 Earnings Call Transcript
May 3 HOLX Hologic's (HOLX) Q2 Earnings Beat Estimates, 2024 View Up
May 3 HOLX Q2 2024 Hologic Inc Earnings Call
May 3 HOLX Hologic, Inc. (HOLX) Q2 2024 Earnings Call Transcript
May 3 HOLX Hologic (HOLX) Reports Q2 Earnings: What Key Metrics Have to Say
May 2 HOLX Hologic Inc. (HOLX) Surpasses Q2 Fiscal 2024 Earnings and Revenue Estimates
May 2 HOLX Hologic (HOLX) Q2 Earnings and Revenues Beat Estimates
May 2 HOLX Hologic Fiscal Q2 Earnings, Revenue Decline; Q3 Outlook Issued, Fiscal 2024 Estimates Revised -- Shares Up After Hours
May 2 HOLX Hologic Non-GAAP EPS of $1.03 beats by $0.05, revenue of $1.02B beats by $20M
May 2 HOLX Hologic Announces Financial Results for Second Quarter of Fiscal 2024
May 2 PHG Building societies to pay tens of millions to trust scandal victims
May 2 ICAD iCAD to Report First Quarter 2024 Financial Results on May 15, 2024
May 2 PHG One Tech Tip: How to repair an electric toothbrush
May 1 HOLX Hologic Q2 2024 Earnings Preview
May 1 PHG Koninklijke Philips N.V. (NYSE:PHG) Q1 2024 Earnings Call Transcript
May 1 HOLX Will These 5 MedTech Stocks Beat Forecasts This Earnings Season?
May 1 RDNT RadNet (RDNT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
May 1 PHG Koninklijke Philips: Major Overhang Removed
Mammography

Mammography (also called mastography) is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast for diagnosis and screening. The goal of mammography is the early detection of breast cancer, typically through detection of characteristic masses or microcalcifications.
As with all X-rays, mammograms use doses of ionizing radiation to create images. These images are then analyzed for abnormal findings. It is usual to employ lower-energy X-rays, typically Mo (K-shell x-ray energies of 17.5 and 19.6 keV) and Rh (20.2 and 22.7 keV) than those used for radiography of bones. Ultrasound, ductography, positron emission mammography (PEM), and magnetic resonance imaging (MRI) are adjuncts to mammography. Ultrasound is typically used for further evaluation of masses found on mammography or palpable masses not seen on mammograms. Ductograms are still used in some institutions for evaluation of bloody nipple discharge when the mammogram is non-diagnostic. MRI can be useful for further evaluation of questionable findings, as well as for screening pre-surgical evaluation in patients with known breast cancer, in order to detect additional lesions that might change the surgical approach, for example, from breast-conserving lumpectomy to mastectomy. Other procedures being investigated include tomosynthesis.
For the average woman, the U.S. Preventive Services Task Force recommends (2016) mammography every two years between the ages of 50 and 74, concluding that "the benefit of screening mammography outweighs the harms by at least a moderate amount from age 50 to 74 years and is greatest for women in their 60s". The American College of Radiology and American Cancer Society recommend yearly screening mammography starting at age 40. The Canadian Task Force on Preventive Health Care (2012) and the European Cancer Observatory (2011) recommend mammography every 2 to 3 years between ages 50 and 69. These task force reports point out that in addition to unnecessary surgery and anxiety, the risks of more frequent mammograms include a small but significant increase in breast cancer induced by radiation. Additionally, mammograms should not be performed with increased frequency in patients undergoing breast surgery, including breast enlargement, mastopexy, and breast reduction. The Cochrane Collaboration (2013) concluded after ten years that trials with adequate randomization did not find an effect of mammography screening on total cancer mortality, including breast cancer. The authors of this Cochrane review write: "If we assume that screening reduces breast cancer mortality by 15% and that overdiagnosis and over-treatment is at 30%, it means that for every 2,000 women invited for screening throughout 10 years, one will avoid dying of breast cancer and 10 healthy women, who would not have been diagnosed if there had not been screening, will be treated unnecessarily. Furthermore, more than 200 women will experience important psychological distress including anxiety and uncertainty for years because of false positive findings." The authors conclude that the time has come to re-assess whether universal mammography screening should be recommended for any age group. They state that universal screening may not be reasonable. The Nordic Cochrane Collection updated research in 2012 and stated that advances in diagnosis and treatment make mammography screening less effective today, rendering it “no longer effective.” They conclude that “it therefore no longer seems reasonable to attend” for breast cancer screening at any age, and warn of misleading information on the internet.Mammography has a false-negative (missed cancer) rate of at least ten percent. This is partly due to dense tissue obscuring the cancer and the appearance of cancer on mammograms having a large overlap with the appearance of normal tissue. A meta-analysis review of programs in countries with organized screening found a 52% over-diagnosis rate.

Browse All Tags